- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02065596
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective
1. To evaluate the safety and feasibility of hematopoietic stem cell transplant (HSCT) after treatment with fludarabine in adult patients with Sickle Cell Disease (SCD).
Secondary Objective(s), in HSCT for SCD
- To evaluate the rates of disease-free and overall survival in both MSD and alternate graft donor (MUD, haploidentical, or cord blood-derived) recipients
- To evaluate fertility in matched sibling and alternate-donor graft recipients
- To evaluate GVHD rates in MSD and Alternate Graft Donor recipients in SCD.
- To evaluate cerebral, pulmonary, renal, and generalized vasculopathy before and after HSCT in SCD.
- To evaluate hematopoiesis and erythropoiesis before and before HSCT in SCD.
- Modulation of SCD Phenotype by Allogeneic Transplantation. Rigorous clinical follow-up will be performed, per routine care, to evaluate those consequences of SCD that will be modified by allogeneic transplantation in the short-term (4-12 weeks), in the medium-term (12-24 weeks) and in the long-term (>24 weeks). Short-term changes would include disappearance of stress hematopoiesis and erythropoiesis; medium- and long-term changes would include effects on pain, fertility (TSH, LH), cognition (routine cognitive assessments), and end-organ damage (including urine albumin-to-creatinine ratios and tricuspid regurgitant jet velocities, as indicated).
Procedures:
The study will start with at least 10 and up to 25 patients. They will be given the lowest starting dose of fludarabine. This is done to make sure it is safe. Researchers will watch the patients during what is called the dose-limiting toxicity (DLT) period. Their safety will be monitored by a Safety Monitoring Committee, which is made up of people who run research studies. The study will not take new patients until the DLT period is done.
If at least 3 of the 10 patients enrolled do not benefit, the maximum tolerated dose (MTD) will be considered exceeded. After the DLT period is complete, patients will receive a stem cell transplant from a genetically matched donor. Patients will be continued to be monitored for a year after the transplant.
To prepare for the transplant patients will have to undergo the following treatments:
- an exchange transfusion
a stem cell graft infusion from either a:
- perfectly matched sibling donor (called MSD),
- perfectly matched but unrelated donor (called MUD),
- a half-matched related donor (called Haploidentical), or
- a cord blood donor
- rabbit antithymocyte globulin (ATG)
- cytoxan (a type of chemotherapy)
- Fludarabine (you get this medicine a few weeks before transplant and again, as part of the routine chemotherapy treatment). This is the main drug being studies in this research
- total body irradiation (also called TBI)
- tacrolimus, mycophenolate (MMF) and/or methotrexate (MTX). These drugs will weaken your immune system. They are given to lower your chances of getting GVHD and rejecting the donor cells.
Patients will be in the study for approximately 14 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Kirsten Boughan, DO
- Phone Number: 1-800-641-2422
- Email: CTUReferral@UHhospitals.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have one of the following inherited hemoglobin gene disorders:
- a. Hemoglobin SS
- b. Hemoglobin SC
- c. Hemoglobin S-Beta-zero-Thalassemia or
- d. Hemoglobin S-Beta-plus Thalassemia with an episode of multi-organ failure within 5 years of eligibility
Patients must meet one of the following risk criteria:
Low Risk (Red Light. Stop and consider therapy closely): Must have matched sibling donor grafts, failed conventional therapy as determined by the PI, and evidence for morbid disease (one of the following):
- a. 2 or more painful episode/year (requiring Emergency Department or inpatient care) x 2 years or
- b. 1 or more diagnoses of Acute Chest Syndrome within 5 years, or
- c. 2-year mortality 5-10% or
- d. Baseline LDH>600 IU or
- e. History of sepsis, with or without a WBC>13.5, or
- f. On chronic transfusions
Moderate Risk (Yellow Light. Reasonable to proceed, but with caution): May have alternate donor grafts (haploidentical or matched unrelated donor), if MSD is not available. Must have history of high-level vasculopathy, as defined by at least one of the criteria below:
- a. Urine Albumin to Creatinine Ratio of >300mg/g or eGFR 50-90 ml/min x 2 evaluations within 3 months or
- b. History of overt clinical stroke, or progressive cerebral vasculopathy radiographically or
- c. 1 or more diagnoses of Acute Chest Syndrome, multi-organ failure, or sickle hepatopathy within 7 years, or
- d. Excessively morbid disease manifest as VOCs at a rate of 2 or more per year x 2-years or uncontolled retinal disease attributed to SCD. These patients can be considered for moderate-risk alternate donor transplants. The palliative nature of the transplant will be explicit in the consent.
e. 2-year mortality >10-15%
- i. Baseline WBC>13.5 and on chronic transfusions or baseline LDH>600 or age >35 years old,
- ii. Baseline TRV ≥3 m/s,
- iii. Chronic transfusion therapy and age >35 years old or male gender,
- iv. Baseline LDH>600 and age >35 years old or history of sepsis
- v. History of sepsis and age >35 years old or male gender.
- f. History of multi-organ failure
High Risk (Green light, proceed if possible): All donor types are eligible. Must have high risk disease and a >15% risk of 2-year mortality as defined by at least one of the criteria below.
- a. Baseline TRV ≥3 m/s and baseline WBC >13.5 or on chronic transfusions or history of sepsis or age >35 years old,
- b. Baseline WBC>13.5 and chronic transfusions or baseline LDH>600 or age >35 years old
- c. Age >35 years old and chronic transfusions
To determine eligibility as a bone marrow transplant patient:
Available suitable donor
- a. 6/6 HLA-matched sibling donor (HLA A, B, and DRB1), bone marrow only
- b. 8/8 HLA-matched unrelated donor (HLA A, B, C, DRB1), bone marrow only
- c. 4/8, 5/8, 6/8, 7/8 Haploidentical donor, bone marrow only
Patients must have adequate hematologic, hepatic, and renal function as defined below:
- Direct bilirubin within 3 X normal institutional limits
- ALT (SGPT) < 3 X institutional upper limit of normal
- Creatinine clearance >21 mL/min/1.73 m^2 for subjects with creatinine clearance values below 50 mL/min/1.73 m^2, the principal investigator may use discretion for appropriate fludarabine dose adjustment as noted.
- Patients must have adequate pulmonary function as defined by Pulmonary function: DLCO r40% (adjusted for hemoglobin) and FEV1r50%.
- Contraception/Child Bearing The effects of Fludarabine, cytoxan, ATG, tacrolimus/sirolimus and MTX are cumulatively known to be deleterious to the health of the developing human fetus. For this reason, and because of teratogenic potential, all women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) for the duration of study participation and for 12 months after completing treatment.
- Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Red cell alloimmunization to a degree that precludes extended transfusion
- Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Subjects must not have evidence of impaired liver function due to iron overload, +/- hepatitis. Patients will be evaluated by liver consult if ferritin >1500, history of hepatitis,or ALTis ≥3 X Upper limit of normal (ULN). Recommended evaluations could include liver biopsy if there is evidence for significant hepatic iron deposition or fibrosis/cirrhosis on T2* MRI of the liver.
- eGFR <21 ml/min
- ≥2.0 liter-per-minute pm home oxygen requirement
- An estimated Left Ventricular Ejection Fraction ≤40% (echo or MUGA)
- Hepatic cirrhosis (Biopsy Proven)
- HIV positive, ineligible because of the increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
- Pregnant or breastfeeding women are excluded from this study because the immunomodulatory treatment, preparative regimen, and anti-GVHD therapy contain agents with the potential for teratogenic or abortifacient effects.
- Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within 1 month prior to starting the conditioning regimen. Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen.
- Prior allogeneic marrow or stem cell transplantation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Immunomodulation with Fludarabine prior to HSCT
Fludarabine given beginning at 25mgm/m2 three times per day.
Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
|
the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed.
If a patient experiences DLT, defined as failure to engraft.
In which case, the patient may be advanced to two higher doses.
Other Names:
Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood.
Patients will be followed for the following year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Probability of Engraftment
Time Frame: 42 Days after transplant
|
The number of patients with engraftment (as defined as recovery of ANC to 500 cells per cubic mm) compared to the total number of patients treated as a function of the patient's age.
|
42 Days after transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean time to engraftment
Time Frame: 42 Days after transplant
|
The average time to for engraftment (as defined as recovery of ANC to 500 cells per cubic mm) to occur estimated using a Kaplan-Meier curve as a function of the patient's age.
|
42 Days after transplant
|
Disease Progression
Time Frame: 1 year
|
The average time (in days) to disease progression estimated using a Kaplan-Meier curve
|
1 year
|
Overall Survival
Time Frame: 1 year
|
The average time (in days) patients are alive after treatment estimated using a Kaplan-Meier curve
|
1 year
|
Follicular Stimulating Hormone Levels
Time Frame: 1 year
|
Estimated difference in changes in Follicular Stimulating Hormone Levels after transplant, among patients with matched sibling donors compared to patients with alternate donors.
|
1 year
|
Luteinizing Hormone Levels
Time Frame: 1 year
|
Estimated difference in changes in Luteinizing hormone Levels after transplant, among patients with matched sibling donors compared to patients with alternate donors.
|
1 year
|
Testosterone Levels
Time Frame: 1 year
|
Estimated difference in changes in Testosterone Levels after transplant, among male patients with matched sibling donors compared to patients with alternate donors.
|
1 year
|
Graft versus Host Disease
Time Frame: 1 year
|
The number patients with Grade III-IVGraft versus Host Disease as defined by CTCAE v4.0 in matched sibling compared to alternate-donor graft recipients
|
1 year
|
Cerebral Vasculopathy
Time Frame: 1 year
|
Vasculopathy may clinically manifest as a history of stroke.
The difference in number of strokes before and after transplantation will be evaluated with paired statistical tests (t-test or McNemar).
|
1 year
|
Renal Vasculopathy
Time Frame: 1 year
|
Vasculopathy may clinically manifest as macroalbuminuria (≥300mg/g urinary albumin-to-creatinine ratio) or as a depressed estimated glomerular flow rate (eGFR).
Evidence of renal vasculopathy before and after transplantation will be evaluated with paired statistical tests (t-test or McNemar).
|
1 year
|
Pulmonary Vasculopathy
Time Frame: 1 year
|
Vasculopathy may clinically manifest as pulmonary arterial systolic pressure (PASP) by echo.
Difference in PASP levels before and after transplantation will be evaluated with paired statistical tests (t-test or McNemar).
|
1 year
|
Hematopoiesis
Time Frame: 1 year
|
Levels of stress hematopoiesis will be assessed by measuring telomere lengths with PCR before and after transplantation.
These levels will be evaluated with paired statistical tests (t-test or McNemar).
|
1 year
|
Erythropoiesis
Time Frame: 1 year
|
Levels of stress erythropoiesis will be assessed by measuring telomere lengths with PCR before and after transplantation.
These levels will be evaluated with paired statistical tests (t-test or McNemar).
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Fludarabine
- Fludarabine phosphate
Other Study ID Numbers
- CASE12Z13
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Fludarabine
-
National Institute of Arthritis and Musculoskeletal...CompletedPsoriasis | Arthritis, PsoriaticUnited States
-
Nantes University HospitalCyceronNot yet recruiting
-
Naoyuki G. Saito, M.D., Ph.D.WithdrawnAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Lymphocytic LeukemiaUnited States
-
Emory UniversityCompletedSickle Cell Disease | Bone Marrow TransplantationUnited States
-
National Institute of Arthritis and Musculoskeletal...CompletedSystemic Lupus Erythematosus | Glomerulonephritis | Lupus NephritisUnited States
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceCompletedUntreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma PatientsFrance
-
University of Illinois at ChicagoCompletedAcute Myeloid Leukemia | Polycythemia Vera | Multiple Myeloma | Myelofibrosis | Acute Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Myeloproliferative Disorder | Hodgkin's Disease | Malignant Lymphoma | Lymphocytic LeukemiaUnited States
-
Zhujiang HospitalFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsUnknownLeukemia Relapse | Chronic Graft-versus-host-disease
-
Massachusetts General HospitalTerminatedMultiple Myeloma | Hodgkin Disease | Non Hodgkin's LymphomaUnited States
-
German CLL Study GroupCompletedAnemia | Chronic Lymphocytic LeukemiaGermany